Lipid Nanoparticles Market by Product (Ionizable lipids, Phospholipids, Neutral Lipids), Type (SLNs, NLCs), Molecule (siRNA, mRNA), Application, Service Type (Formulation Development, Manufacturing), End User, Region - Global Forecast to 2031

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 MARKET SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 REGIONS CONSIDERED
  • 1.3.3 INCLUSIONS & EXCLUSIONS
  • 1.3.4 YEARS CONSIDERED
  • 1.3.5 CURRENCY CONSIDERED
• 1.4 MARKET STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 MARKET HIGHLIGHTS & KEY INSIGHTS
• 2.2 KEY MARKET PARTICIPANTS: MAPPING OF STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS IN LNP RAW MATERIALS & SERVICES MARKET
• 2.4 HIGH GROWTH SEGMENTS
• 2.5 REGIONAL SNAPSHOT: MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 LNP RAW MATERIALS & SERVICES MARKET OVERVIEW
• 3.2 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT TYPE AND COUNTRY
• 3.3 LNP RAW MATERIALS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 3.4 LNP RAW MATERIALS MARKET SHARE, BY END USER, 2026 VS 2031 (%)
• 3.5 LNP SERVICES MARKET SHARE, BY END USER, 2026 VS 2031 (%)

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Increasing use of lipid nanoparticles in anti-cancer therapies
    • 4.2.1.2 High uptake in RNA-based therapeutic research
    • 4.2.1.3 Growing government focus on R&D for LNP-based drugs
  • 4.2.2 RESTRAINTS
    • 4.2.2.1 Stringent regulatory requirements
  • 4.2.3 OPPORTUNITIES
    • 4.2.3.1 Growing demand for advanced drug delivery systems
  • 4.2.4 CHALLENGES
    • 4.2.4.1 Challenges associated with LNP formulation
• 4.3 UNMET NEEDS & WHITE SPACES
• 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 PORTER'S FIVE FORCES ANALYSIS
  • 5.1.1 INTENSITY OF COMPETITIVE RIVALRY
  • 5.1.2 BARGAINING POWER OF SUPPLIERS
  • 5.1.3 BARGAINING POWER OF BUYERS
  • 5.1.4 THREAT OF SUBSTITUTES
  • 5.1.5 THREAT OF NEW ENTRANTS
• 5.2 MACROECONOMIC OUTLOOK
  • 5.2.1 INTRODUCTION
  • 5.2.2 GDP TRENDS & FORECAST
  • 5.2.3 GDP TRENDS & FORECAST
• 5.3 VALUE CHAIN ANALYSIS
  • 5.3.1 RAW MATERIALS
  • 5.3.2 SERVICES
• 5.4 ECOSYSTEM ANALYSIS
• 5.5 PRICING ANALYSIS
  • 5.5.1 AVERAGE SELLING PRICE TREND, BY KEY PLAYER, 2023-2025
  • 5.5.2 AVERAGE SELLING PRICE TREND, BY TYPE (2023-2025)
• 5.6 KEY CONFERENCES & EVENTS, 2026-2027
• 5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.8 INVESTMENT & FUNDING SCENARIO
• 5.9 IMPACT OF 2025 US TARIFFS-LIPID NANOPARTICLES MARKET
  • 5.9.1 INTRODUCTION
  • 5.9.2 PRICE IMPACT ANALYSIS
  • 5.9.3 IMPACT ON COUNTRIES/REGIONS
    • 5.9.3.1 US
    • 5.9.3.2 Europe
    • 5.9.3.3 Asia Pacific
  • 5.9.4 IMPACT ON END-USER INDUSTRIES
    • 5.9.4.1 Pharmaceutical & biotechnology companies
    • 5.9.4.2 CROs & CDMOs
    • 5.9.4.3 Academic & research institutes

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 TECHNOLOGY ANALYSIS
  • 6.1.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1.1 Nanotechnology-based drug delivery
    • 6.1.1.2 Nucleic acid delivery
  • 6.1.2 COMPLEMENTARY TECHNOLOGIES
    • 6.1.2.1 Drug encapsulation techniques
    • 6.1.2.2 Surface modification and functionalization technologies
  • 6.1.3 ADJACENT TECHNOLOGIES
    • 6.1.3.1 Biotechnology & genetic engineering technologies
    • 6.1.3.2 Nanotechnology-based formulation techniques
• 6.2 TECHNOLOGY/PRODUCT ROADMAP
• 6.3 PATENT ANALYSIS
  • 6.3.1 TOP APPLICANTS/OWNERS (COMPANIES) FOR LIPID NANOPARTICLE PATENTS, 2015-2025
• 6.4 FUTURE APPLICATIONS
• 6.5 IMPACT OF GENERATIVE AI ON LIPID NANOPARTICLES MARKET
  • 6.5.1 BEST PRACTICES IN LIPID NANOPARTICLE WORKFLOWS
  • 6.5.2 CASE STUDIES OF AI IMPLEMENTATION
  • 6.5.3 INTERCONNECTED ADJACENT ECOSYSTEMS & IMPACT ON MARKET PLAYERS
  • 6.5.4 CLIENTS' READINESS TO ADOPT GENERATIVE AI

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

• 7.1 REGIONAL REGULATIONS & COMPLIANCE
  • 7.1.1 REGULATORY SCENARIO
  • 7.1.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.3 INDUSTRY STANDARDS
• 7.2 SUSTAINABILITY INITIATIVES
• 7.3 IMPACT OF REGULATORY POLICIES ON SUSTAINABILITY INITIATIVES
• 7.4 CERTIFICATIONS, LABELING, AND ECO-STANDARDS

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE RAW MATERIALS, BY END USER
  • 8.2.3 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE SERVICES, BY END USER
• 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 LNP RAW MATERIALS MARKET, BY PRODUCT

• 9.1 INTRODUCTION
• 9.2 IONIZABLE LIPIDS
  • 9.2.1 HIGH DEMAND FOR MRNA-BASED VACCINES TO PROPEL MARKET
• 9.3 PEGYLATED LIPIDS
  • 9.3.1 GROWING FOCUS ON NUCLEIC ACID MEDICINES TO BOOST DEMAND
• 9.4 NEUTRAL LIPIDS
  • 9.4.1 ENHANCED STABILITY AND HIGH UPTAKE IN THERAPEUTIC APPLICATIONS TO DRIVE MARKET
• 9.5 PHOSPHOLIPIDS
  • 9.5.1 BIOLOGICAL COMPATIBILITY AND CUSTOMIZATION FEATURES TO SUPPORT MARKET GROWTH
• 9.6 KITS & REAGENTS
  • 9.6.1 ADVANCEMENTS IN LNP FORMULATION TECHNIQUES TO DRIVE MARKET
• 9.7 OTHER FORMULATION MATERIALS

10 LNP RAW MATERIALS MARKET, BY LNP TYPE

• 10.1 INTRODUCTION
• 10.2 SOLID LIPID NANOPARTICLES (SLNS)
  • 10.2.1 ADVANTAGES OVER CONVENTIONAL DRUG CARRIERS TO DRIVE MARKET
• 10.3 NANOSTRUCTURED LIPID CARRIERS (NLCS)
  • 10.3.1 HIGH DRUG LOADING CAPACITY TO PROPEL MARKET
• 10.4 OTHER LNP TYPES

11 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE

• 11.1 INTRODUCTION
• 11.2 SIRNA
  • 11.2.1 GROWING FOCUS ON TARGETED DRUG DELIVERY TO DRIVE MARKET
• 11.3 MRNA
  • 11.3.1 GROWING UPTAKE IN VACCINE DEVELOPMENT TO PROPEL MARKET
• 11.4 OTHER MOLECULES

12 LNP RAW MATERIALS MARKET, BY APPLICATION

• 12.1 INTRODUCTION
• 12.2 COMMERCIAL APPLICATIONS
  • 12.2.1 POLYNEUROPATHY
    • 12.2.1.1 Ability to provide targeted & sustained release of therapeutic agents to boost demand
  • 12.2.2 OTHER COMMERCIAL APPLICATIONS
• 12.3 CLINICAL APPLICATIONS
  • 12.3.1 COVID-19
    • 12.3.1.1 Threat of evolving emerging variants to fuel uptake
  • 12.3.2 CANCER
    • 12.3.2.1 Increasing focus on oncology therapeutics to drive market
  • 12.3.3 OTHER CLINICAL APPLICATIONS

13 LNP RAW MATERIALS MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 13.2.1 INCREASING DRUG DEVELOPMENT ACTIVITIES TO FUEL MARKET
• 13.3 ACADEMIC & RESEARCH INSTITUTES
  • 13.3.1 HIGH FOCUS ON R&D FOR GENE THERAPY AND MEDICATION ADMINISTRATION TO DRIVE MARKET
• 13.4 CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS (CDMOS)
  • 13.4.1 GROWING OUTSOURCING OF LNP FORMULATION SERVICES TO PROPEL MARKET

14 LNP SERVICES MARKET, BY SERVICE TYPE

• 14.1 INTRODUCTION
• 14.2 FORMULATION DEVELOPMENT SERVICES
  • 14.2.1 GROWING FOCUS ON TARGETED & EFFECTIVE DRUG DELIVERY TO PROPEL MARKET
• 14.3 MANUFACTURING SERVICES
  • 14.3.1 RISING DEMAND FOR LIPID-BASED CARRIERS FOR GENE THERAPY AND VACCINE DEVELOPMENT TO DRIVE MARKET
• 14.4 OTHER SERVICES

15 LNP SERVICES MARKET, BY END USER

• 15.1 INTRODUCTION
• 15.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 15.2.1 DRUG DEVELOPMENT & COMMERCIALIZATION TO PROPEL MARKET
• 15.3 ACADEMIC & RESEARCH INSTITUTES
  • 15.3.1 ACCESS TO ADVANCED INFRASTRUCTURE AND SPECIALIZED EXPERTISE TO SUPPORT MARKET GROWTH

16 LIPID NANOPARTICLES MARKET, BY REGION

• 16.1 INTRODUCTION
• 16.2 NORTH AMERICA
  • 16.2.1 US
    • 16.2.1.1 High pharmaceutical R&D expenditure to drive market
  • 16.2.2 CANADA
    • 16.2.2.1 Growing focus on personalized medicine to drive market
• 16.3 EUROPE
  • 16.3.1 GERMANY
    • 16.3.1.1 Rising development activities for LNP production to drive market
  • 16.3.2 UK
    • 16.3.2.1 Pioneering research programs for drug delivery systems to boost demand
  • 16.3.3 FRANCE
    • 16.3.3.1 Government funding for proteomics and genomics research to support market growth
  • 16.3.4 ITALY
    • 16.3.4.1 Growth in life sciences research to propel market
  • 16.3.5 SPAIN
    • 16.3.5.1 Growing demand for cancer therapeutics to drive market
  • 16.3.6 REST OF EUROPE
• 16.4 ASIA PACIFIC
  • 16.4.1 CHINA
    • 16.4.1.1 Low manufacturing costs and rising outsourcing of services to CDMOs to drive market
  • 16.4.2 JAPAN
    • 16.4.2.1 Demand for LNP-based mRNA vaccines to fuel market
  • 16.4.3 INDIA
    • 16.4.3.1 Growth in pharmaceutical industry to drive market
  • 16.4.4 SOUTH KOREA
    • 16.4.4.1 Rising number of clinical trials to boost demand
  • 16.4.5 AUSTRALIA
    • 16.4.5.1 Growing requirement for innovative drug delivery systems to propel market
  • 16.4.6 REST OF ASIA PACIFIC
• 16.5 LATIN AMERICA
  • 16.5.1 BRAZIL
    • 16.5.1.1 Global manufacturing hub for pharmaceutical drugs to fuel uptake
  • 16.5.2 MEXICO
    • 16.5.2.1 Large target patient population and demand for novel drug delivery technology to drive market
  • 16.5.3 REST OF LATIN AMERICA
• 16.6 MIDDLE EAST
  • 16.6.1 GCC COUNTRIES
    • 16.6.1.1 Economic & healthcare expansion to support market growth
  • 16.6.2 REST OF MIDDLE EAST
• 16.7 AFRICA
  • 16.7.1 IMPROVEMENTS IN HEALTHCARE INFRASTRUCTURE TO SUPPORT MARKET GROWTH

17 COMPETITIVE LANDSCAPE

• 17.1 INTRODUCTION
• 17.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 17.3 REVENUE ANALYSIS 2019-2025
• 17.4 MARKET SHARE ANALYSIS
  • 17.4.1 LNP RAW MATERIALS MARKET
  • 17.4.2 LNP SERVICES MARKET
• 17.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 17.5.1 STARS
  • 17.5.2 EMERGING LEADERS
  • 17.5.3 PERVASIVE PLAYERS
  • 17.5.4 PARTICIPANTS
  • 17.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 17.5.5.1 Company footprint
    • 17.5.5.2 Region footprint
    • 17.5.5.3 Product footprint
    • 17.5.5.4 Application footprint
    • 17.5.5.5 Service footprint
• 17.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 17.6.1 PROGRESSIVE COMPANIES
  • 17.6.2 RESPONSIVE COMPANIES
  • 17.6.3 DYNAMIC COMPANIES
  • 17.6.4 STARTING BLOCKS
  • 17.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2025
• 17.7 COMPANY VALUATION & FINANCIAL METRICS
  • 17.7.1 FINANCIAL METRICS
  • 17.7.2 COMPANY VALUATION
• 17.8 BRAND/PRODUCT COMPARISON ANALYSIS
• 17.9 COMPETITIVE SCENARIO
  • 17.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
  • 17.9.2 DEALS
  • 17.9.3 EXPANSIONS

18 COMPANY PROFILES

• 18.1 KEY PLAYERS
  • 18.1.1 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC)
    • 18.1.1.1 Business overview
    • 18.1.1.2 Products/Services offered
    • 18.1.1.3 Recent developments
      • 18.1.1.3.1 Product launches
      • 18.1.1.3.2 Deals
      • 18.1.1.3.3 Expansions
      • 18.1.1.3.4 Other developments
    • 18.1.1.4 MnM view
      • 18.1.1.4.1 Key strengths
      • 18.1.1.4.2 Strategic choices
      • 18.1.1.4.3 Weaknesses & competitive threats
  • 18.1.2 MERCK KGAA
    • 18.1.2.1 Business overview
    • 18.1.2.2 Products/Services offered
    • 18.1.2.3 Recent developments
      • 18.1.2.3.1 Service launches
      • 18.1.2.3.2 Expansions
    • 18.1.2.4 MnM view
      • 18.1.2.4.1 Key strengths
      • 18.1.2.4.2 Strategic choices
      • 18.1.2.4.3 Weaknesses & competitive threats
  • 18.1.3 EVONIK INDUSTRIES AG
    • 18.1.3.1 Business overview
    • 18.1.3.2 Products/Services offered
    • 18.1.3.3 Recent developments
      • 18.1.3.3.1 Deals
      • 18.1.3.3.2 Expansions
    • 18.1.3.4 MnM view
      • 18.1.3.4.1 Key strengths
      • 18.1.3.4.2 Strategic choices
      • 18.1.3.4.3 Weaknesses & competitive threats
  • 18.1.4 NIPPON FINE CHEMICAL
    • 18.1.4.1 Business overview
    • 18.1.4.2 Products/Services offered
    • 18.1.4.3 MnM view
      • 18.1.4.3.1 Key strengths
      • 18.1.4.3.2 Strategic choices
      • 18.1.4.3.3 Weaknesses & competitive threats
  • 18.1.5 NOF CORPORATION
    • 18.1.5.1 Business overview
    • 18.1.5.2 Products/Services offered
    • 18.1.5.3 Recent developments
      • 18.1.5.3.1 Deals
      • 18.1.5.3.2 Expansions
    • 18.1.5.4 MnM view
      • 18.1.5.4.1 Key strengths
      • 18.1.5.4.2 Strategic choices
      • 18.1.5.4.3 Weaknesses & competitive threats
  • 18.1.6 FUJIFILM PHARMACEUTICALS U.S.A., INC. (FUJIFILM HOLDINGS CORPORATION)
    • 18.1.6.1 Business overview
    • 18.1.6.2 Products/Services offered
    • 18.1.6.3 Recent developments
      • 18.1.6.3.1 Deals
      • 18.1.6.3.2 Expansions
  • 18.1.7 PRECISION NANOSYSTEMS (CYTIVA)
    • 18.1.7.1 Business overview
    • 18.1.7.2 Products/Services offered
    • 18.1.7.3 Recent developments
      • 18.1.7.3.1 Service launches
  • 18.1.8 EQT AB
    • 18.1.8.1 Business overview
    • 18.1.8.2 Products/Services offered
    • 18.1.8.3 Recent developments
      • 18.1.8.3.1 Deals
      • 18.1.8.3.2 Expansions
  • 18.1.9 EMERGENT
    • 18.1.9.1 Business overview
    • 18.1.9.2 Products/Services offered
  • 18.1.10 EUROAPI
    • 18.1.10.1 Business overview
    • 18.1.10.2 Products/Services offered
  • 18.1.11 CAYMAN CHEMICAL
    • 18.1.11.1 Business overview
    • 18.1.11.2 Products/Services offered
    • 18.1.11.3 Recent developments
      • 18.1.11.3.1 Product launches
      • 18.1.11.3.2 Deals
  • 18.1.12 CORDENPHARMA
    • 18.1.12.1 Business overview
    • 18.1.12.2 Products/Services offered
    • 18.1.12.3 Recent developments
      • 18.1.12.3.1 Product launches
      • 18.1.12.3.2 Deals
      • 18.1.12.3.3 Expansions
  • 18.1.13 GATTEFOSSE
    • 18.1.13.1 Business overview
    • 18.1.13.2 Products/Services offered
  • 18.1.14 ACUITAS THERAPEUTICS
    • 18.1.14.1 Business overview
    • 18.1.14.2 Products/Services offered
    • 18.1.14.3 Recent developments
      • 18.1.14.3.1 Deals
  • 18.1.15 IOI OLEO GMBH
    • 18.1.15.1 Business overview
    • 18.1.15.2 Products/Services offered
• 18.2 OTHER PLAYERS
  • 18.2.1 CREATIVE BIOLABS
  • 18.2.2 CURAPATH
  • 18.2.3 LIPOID GMBH
  • 18.2.4 NANOCS INC.
  • 18.2.5 MEDKOO BIOSCIENCES, INC.
  • 18.2.6 POLYSCIENCES INC.
  • 18.2.7 BIOVECTRA
  • 18.2.8 ASCENDIA PHARMACEUTICALS
  • 18.2.9 CURIA GLOBAL, INC.
  • 18.2.10 VERNAL BIOSCIENCES

19 RESEARCH METHODOLOGY

• 19.1 RESEARCH DATA
  • 19.1.1 SECONDARY DATA
  • 19.1.2 PRIMARY DATA
• 19.2 MARKET ESTIMATION METHODOLOGY
  • 19.2.1 GLOBAL MARKET ESTIMATION
  • 19.2.2 INSIGHTS OF PRIMARY EXPERTS
• 19.3 MARKET GROWTH RATE PROJECTIONS
• 19.4 MARKET BREAKDOWN AND DATA TRIANGULATION
• 19.5 RESEARCH ASSUMPTIONS
• 19.6 RESEARCH LIMITATIONS
• 19.7 RISK ANALYSIS

20 APPENDIX

• 20.1 DISCUSSION GUIDE
• 20.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 20.3 CUSTOMIZATION OPTIONS
• 20.4 RELATED REPORTS
• 20.5 AUTHOR DETAILS

List of Tables

• TABLE 1 LIPID NANOPARTICLES MARKET: IMPACT ANALYSIS
• TABLE 2 IMPACT OF PORTER'S FIVE FORCES ON THE LIPID NANOPARTICLES MARKET
• TABLE 3 LIPID NANOPARTICLES MARKET: ROLE IN ECOSYSTEM
• TABLE 4 AVERAGE SELLING PRICE TREND OF LNP PRODUCTS, BY KEY PLAYER, 2023-2025 (USD)
• TABLE 5 AVERAGE SELLING PRICE TREND OF LNP PRODUCTS, BY TYPE, 2023-2025 (USD)
• TABLE 6 LIPID NANOPARTICLES MARKET: KEY CONFERENCES & EVENTS (2026-2027)
• TABLE 7 LIPID NANOPARTICLE MARKET: INDICATIVE LIST OF PATENTS
• TABLE 8 CASE STUDIES OF AI IMPLEMENTATION IN LIPID NANOPARTICLES MARKET
• TABLE 9 CLIENTS' TOP READINESS TO ADOPT GENERATIVE AI IN LIPID NANOPARTICLES MARKET
• TABLE 10 REGULATORY SCENARIO
• TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 12 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 13 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 14 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 15 MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• TABLE 16 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
• TABLE 17 KEY BUYING CRITERIA FOR LNP RAW MATERIALS, BY END USER
• TABLE 18 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE SERVICES, BY END USER
• TABLE 19 LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 20 IONIZABLE LIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 21 NORTH AMERICA: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 22 EUROPE: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 23 ASIA PACIFIC: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 24 LATIN AMERICA: IONIZABLE LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 25 MIDDLE EAST: IONIZABLE LIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 26 PEGYLATED LIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 27 NEUTRAL LIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 28 NORTH AMERICA: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 29 EUROPE: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 30 ASIA PACIFIC: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 31 LATIN AMERICA: NEUTRAL LIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 32 MIDDLE EAST: NEUTRAL LIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 33 PHOSPHOLIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 34 NORTH AMERICA: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 35 EUROPE: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 36 ASIA PACIFIC: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 37 LATIN AMERICA: PHOSPHOLIPIDS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 38 MIDDLE EAST: PHOSPHOLIPIDS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 39 KITS & REAGENTS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 40 OTHER FORMULATION MATERIALS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 41 LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 42 SOLID LIPID NANOPARTICLES MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 43 NORTH AMERICA: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 44 EUROPE: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 45 ASIA PACIFIC: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 46 LATIN AMERICA: SOLID LIPID NANOPARTICLES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 47 MIDDLE EAST: SOLID LIPID NANOPARTICLES MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 48 NANOSTRUCTURED LIPID CARRIERS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 49 NORTH AMERICA: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 50 EUROPE: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 51 ASIA PACIFIC: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 52 LATIN AMERICA: NANOSTRUCTURED LIPID CARRIERS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 53 MIDDLE EAST: NANOSTRUCTURED LIPID CARRIERS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 54 OTHER LNP TYPES MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 55 NORTH AMERICA: OTHER LNP TYPES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 56 EUROPE: OTHER LNP TYPES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 57 ASIA PACIFIC: OTHER LNP TYPES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 58 LATIN AMERICA: OTHER LNP TYPES MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 59 MIDDLE EAST: OTHER LNP TYPES MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 60 LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 61 LNP RAW MATERIALS MARKET FOR SIRNA, BY REGION, 2023-2031 (USD MILLION)
• TABLE 62 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 63 EUROPE: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 64 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 65 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR SIRNA, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 66 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR SIRNA, BY REGION, 2023-2031 (USD MILLION)
• TABLE 67 LNP RAW MATERIALS MARKET FOR MRNA, BY REGION, 2023-2031 (USD MILLION)
• TABLE 68 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 69 EUROPE: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 70 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 71 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR MRNA, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 72 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR MRNA, BY REGION, 2023-2031 (USD MILLION)
• TABLE 73 LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 74 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 75 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 76 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 77 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 78 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER MOLECULES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 79 LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 80 LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 81 LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 82 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 83 EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 84 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 85 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 86 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 87 LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY REGION, 2023-2031 (USD MILLION)
• TABLE 88 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 89 EUROPE: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 90 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 91 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 92 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR POLYNEUROPATHY, BY REGION, 2023-2031 (USD MILLION)
• TABLE 93 LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 94 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 95 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 96 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 97 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 98 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER COMMERCIAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 99 LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 100 LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 101 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 102 EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 103 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 104 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 105 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 106 LNP RAW MATERIALS MARKET FOR 'COVID-19, BY REGION, 2023-2031 (USD MILLION)
• TABLE 107 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19 (CLINICAL APPLICATIONS), BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 108 EUROPE: LNP RAW MATERIALS MARKET FOR COVID-19, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 109 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COVID-19, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 110 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COVID-19, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 111 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COVID-19, BY REGION, 2023-2031 (USD MILLION)
• TABLE 112 LNP RAW MATERIALS MARKET FOR CANCER, BY REGION, 2023-2031 (USD MILLION)
• TABLE 113 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 114 EUROPE: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 115 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 116 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CANCER, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 117 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CANCER, BY REGION, 2023-2031 (USD MILLION)
• TABLE 118 LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 119 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 120 EUROPE: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 121 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR OTHER CLINICAL APPLICATIONS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 122 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR OTHER DISEASES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 123 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR OTHER DISEASES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 124 LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 125 LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 126 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 127 EUROPE: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 128 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 129 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 130 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 131 LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 132 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 133 EUROPE: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 134 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 135 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 136 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 137 LNP RAW MATERIALS MARKET FOR CDMOS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 138 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 139 EUROPE: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 140 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 141 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CDMOS, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 142 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CDMOS, BY REGION, 2023-2031 (USD MILLION)
• TABLE 143 LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
• TABLE 144 FORMULATION DEVELOPMENT SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 145 MANUFACTURING SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 146 OTHER SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 147 LNP SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 148 LNP SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 149 LNP SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2031 (USD MILLION)
• TABLE 150 LNP RAW MATERIALS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 151 LNP SERVICES MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 152 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 153 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 154 NORTH AMERICA: LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
• TABLE 155 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 156 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 157 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 158 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 159 NORTH AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 160 NORTH AMERICA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 161 NORTH AMERICA: LNP SERVICES MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 162 US: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 163 US: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 164 US: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 165 US: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 166 US: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 167 US: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 168 US: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 169 CANADA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 170 CANADA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 171 CANADA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 172 CANADA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 173 CANADA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 174 CANADA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 175 CANADA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 176 EUROPE: LNP RAW MATERIALS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 177 EUROPE: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 178 EUROPE: LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
• TABLE 179 EUROPE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 180 EUROPE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 181 EUROPE: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 182 EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 183 EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 184 EUROPE: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 185 EUROPE: LNP SERVICES MARKET BY END USER, 2023-2031 (USD MILLION)
• TABLE 186 GERMANY: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 187 GERMANY: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 188 GERMANY: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 189 GERMANY: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 190 GERMANY: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 191 GERMANY: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 192 GERMANY: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 193 UK: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 194 UK: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 195 UK: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 196 UK: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 197 UK: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 198 UK: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 199 UK: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 200 FRANCE: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 201 FRANCE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 202 FRANCE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 203 FRANCE: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 204 FRANCE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 205 FRANCE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 206 FRANCE: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 207 ITALY: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 208 ITALY: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 209 ITALY: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 210 ITALY: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 211 ITALY: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 212 ITALY: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 213 ITALY: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 214 SPAIN: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 215 SPAIN: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 216 SPAIN: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 217 SPAIN: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 218 SPAIN: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 219 SPAIN: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 220 SPAIN: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 221 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 222 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 223 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 224 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 225 REST OF EUROPE: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 226 REST OF EUROPE: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 227 REST OF EUROPE: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 228 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 229 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 230 ASIA PACIFIC: LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
• TABLE 231 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 232 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 233 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 234 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 235 ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 236 ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 237 ASIA PACIFIC: LNP SERVICES MARKET BY END USER, 2023-2031 (USD MILLION)
• TABLE 238 CHINA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 239 CHINA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 240 CHINA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 241 CHINA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 242 CHINA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 243 CHINA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 244 CHINA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 245 JAPAN: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 246 JAPAN: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 247 JAPAN: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 248 JAPAN: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 249 JAPAN: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 250 JAPAN: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 251 JAPAN: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 252 INDIA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 253 INDIA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 254 INDIA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 255 INDIA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 256 INDIA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 257 INDIA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 258 INDIA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 259 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 260 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 261 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 262 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 263 SOUTH KOREA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 264 SOUTH KOREA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 265 SOUTH KOREA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 266 AUSTRALIA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 267 AUSTRALIA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 268 AUSTRALIA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 269 AUSTRALIA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 270 AUSTRALIA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 271 AUSTRALIA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 272 AUSTRALIA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 273 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 274 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 275 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 276 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 277 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 278 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 279 REST OF ASIA PACIFIC: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 280 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY COUNTRY, 2023-2031 (USD MILLION)
• TABLE 281 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 282 LATIN AMERICA: LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
• TABLE 283 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 284 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 285 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 286 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 287 LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 288 LATIN AMERICA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 289 LATIN AMERICA: LNP SERVICES MARKET BY END USER, 2023-2031 (USD MILLION)
• TABLE 290 BRAZIL: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 291 BRAZIL: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 292 BRAZIL: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 293 BRAZIL: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 294 BRAZIL: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 295 BRAZIL: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 296 BRAZIL: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 297 MEXICO: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 298 MEXICO: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 299 MEXICO: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 300 MEXICO: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 301 MEXICO: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 302 MEXICO: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 303 MEXICO: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 304 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 305 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 306 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 307 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 308 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 309 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 310 REST OF LATIN AMERICA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 311 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY REGION, 2023-2031 (USD MILLION)
• TABLE 312 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 313 MIDDLE EAST: LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
• TABLE 314 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 315 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 316 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 317 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 318 MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 319 MIDDLE EAST: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 320 MIDDLE EAST: LNP SERVICES MARKET BY END USER, 2023-2031 (USD MILLION)
• TABLE 321 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 322 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 323 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 324 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 325 GCC COUNTRIES: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 326 GCC COUNTRIES: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 327 GCC COUNTRIES: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 328 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 329 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 330 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 331 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 332 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 333 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 334 REST OF MIDDLE EAST: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 335 AFRICA: LNP RAW MATERIALS MARKET, BY PRODUCT, 2023-2031 (USD MILLION)
• TABLE 336 AFRICA: LNP SERVICES MARKET, BY SERVICE TYPE, 2023-2031 (USD MILLION)
• TABLE 337 AFRICA: LNP RAW MATERIALS MARKET, BY LNP TYPE, 2023-2031 (USD MILLION)
• TABLE 338 AFRICA: LNP RAW MATERIALS MARKET, BY MOLECULE TYPE, 2023-2031 (USD MILLION)
• TABLE 339 AFRICA: LNP RAW MATERIALS MARKET, BY APPLICATION, 2023-2031 (USD MILLION)
• TABLE 340 AFRICA: LNP RAW MATERIALS MARKET FOR COMMERCIAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 341 AFRICA: LNP RAW MATERIALS MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2023-2031 (USD MILLION)
• TABLE 342 AFRICA: LNP RAW MATERIALS MARKET, BY END USER, 2023-2031 (USD MILLION)
• TABLE 343 AFRICA: LNP SERVICES MARKET BY END USER, 2023-2031 (USD MILLION)
• TABLE 344 OVERVIEW OF STRATEGIES DEPLOYED BY KEY MANUFACTURING COMPANIES, 2023-2026
• TABLE 345 LNP RAW MATERIALS MARKET: DEGREE OF COMPETITION
• TABLE 346 LNP SERVICES MARKET: TOP SERVICE PROVIDERS (2025)
• TABLE 347 LIPID NANOPARTICLES MARKET: REGION FOOTPRINT
• TABLE 348 LIPID NANOPARTICLES MARKET: PRODUCT FOOTPRINT
• TABLE 349 LIPID NANOPARTICLES MARKET: APPLICATION FOOTPRINT
• TABLE 350 LIPID NANOPARTICLES MARKET: SERVICE FOOTPRINT
• TABLE 351 LIPID NANOPARTICLES MARKET: DETAILED LIST OF KEY STARTUPS/SMES
• TABLE 352 LIPID NANOPARTICLES MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
• TABLE 353 LIPID NANOPARTICLES MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 354 LIPID NANOPARTICLES MARKET: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 355 LIPID NANOPARTICLES MARKET: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
• TABLE 356 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): COMPANY OVERVIEW
• TABLE 357 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): PRODUCTS/ SERVICES OFFERED
• TABLE 358 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
• TABLE 359 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 360 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
• TABLE 361 AVANTI POLAR LIPIDS: OTHER DEVELOPMENTS, JANUARY 2023-SEPTEMBER 2026
• TABLE 362 MERCK KGAA: COMPANY OVERVIEW
• TABLE 363 MERCK KGAA: PRODUCTS/SERVICES OFFERED
• TABLE 364 MERCK KGAA: SERVICE LAUNCHES, JANUARY 2023-SEPTEMBER 2026
• TABLE 365 MERCK KGAA: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
• TABLE 366 EVONIK INDUSTRIES AG: COMPANY OVERVIEW
• TABLE 367 EVONIK INDUSTRIES AG: PRODUCTS/SERVICES OFFERED
• TABLE 368 EVONIK INDUSTRIES AG: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 369 EVONIK INDUSTRIES AG: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
• TABLE 370 NIPPON FINE CHEMICAL CO., LTD.: COMPANY OVERVIEW
• TABLE 371 NIPPON FINE CHEMICAL CO., LTD.: PRODUCTS/SERVICES OFFERED
• TABLE 372 NOF CORPORATION: COMPANY OVERVIEW
• TABLE 373 NOF CORPORATION: PRODUCTS/SERVICES OFFERED
• TABLE 374 NOF CORPORATION: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 375 NOF CORPORATION: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
• TABLE 376 FUJIFILM PHARMACEUTICALS U.S.A., INC.: COMPANY OVERVIEW
• TABLE 377 FUJIFILM PHARMACEUTICALS U.S.A., INC.: PRODUCTS/SERVICES OFFERED
• TABLE 378 FUJIFILM PHARMACEUTICALS U.S.A., INC.: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 379 FUJIFILM PHARMACEUTICALS U.S.A., INC.: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
• TABLE 380 PRECISION NANOSYSTEMS: COMPANY OVERVIEW
• TABLE 381 PRECISION NANOSYSTEMS: PRODUCTS/SERVICES OFFERED
• TABLE 382 PRECISION NANOSYSTEMS: SERVICE LAUNCHES, JANUARY 2023-SEPTEMBER 2026
• TABLE 383 RECIPHARM AB: COMPANY OVERVIEW
• TABLE 384 RECIPHARM AB: PRODUCTS/SERVICES OFFERED
• TABLE 385 RECIPHARM AB: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 386 RECIPHARM AB: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
• TABLE 387 EMERGENT: COMPANY OVERVIEW
• TABLE 388 EMERGENT: PRODUCTS/SERVICES OFFERED
• TABLE 389 EUROAPI: COMPANY OVERVIEW
• TABLE 390 EUROAPI: PRODUCTS/SERVICES OFFERED
• TABLE 391 CAYMAN CHEMICAL: COMPANY OVERVIEW
• TABLE 392 CAYMAN CHEMICAL: PRODUCTS/SERVICES OFFERED
• TABLE 393 CAYMAN CHEMICAL: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
• TABLE 394 CAYMAN CHEMICAL: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 395 CORDENPHARMA: COMPANY OVERVIEW
• TABLE 396 CORDENPHARMA: PRODUCTS/SERVICES OFFERED
• TABLE 397 CORDENPHARMA: PRODUCT LAUNCHES, JANUARY 2023-SEPTEMBER 2026
• TABLE 398 CORDENPHARMA: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 399 CORDENPHARMA: EXPANSIONS, JANUARY 2023-SEPTEMBER 2026
• TABLE 400 GATTEFOSSE: COMPANY OVERVIEW
• TABLE 401 GATTEFOSSE: PRODUCTS/SERVICES OFFERED
• TABLE 402 ACUITAS THERAPEUTICS: COMPANY OVERVIEW
• TABLE 403 ACUITAS THERAPEUTICS: PRODUCTS/SERVICES OFFERED
• TABLE 404 ACUITAS THERAPEUTICS: DEALS, JANUARY 2023-SEPTEMBER 2026
• TABLE 405 IOI OLEO GMBH: COMPANY OVERVIEW
• TABLE 406 IOI OLEO GMBH: PRODUCTS/SERVICES OFFERED
• TABLE 407 IMPACT ANALYSIS OF SUPPLY-SIDE AND DEMAND-SIDE FACTORS
• TABLE 408 RISK ANALYSIS

List of Figures

• FIGURE 1 MARKET SCENARIO
• FIGURE 2 GLOBAL LNP RAW MATERIALS MARKET, 2023-2031
• FIGURE 3 GLOBAL LNP SERVICES MARKET, 2023-2031
• FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LNP RAW MATERIALS MARKET, 2023-2026
• FIGURE 5 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN LNP SERVICES MARKET, 2023-2026
• FIGURE 6 DISRUPTIONS INFLUENCING GROWTH OF LNP RAW MATERIALS & SERVICES MARKET
• FIGURE 7 HIGH-GROWTH SEGMENTS IN LNP RAW MATERIALS & SERVICES MARKET, 2026-2031
• FIGURE 8 ASIA PACIFIC TO REGISTER HIGHEST CAGR IN LNP RAW MATERIALS MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
• FIGURE 9 ASIAC PACIFIC TO REGISTER HIGHEST CAGR IN LNP SERVICES MARKET, IN TERMS OF VALUE, DURING FORECAST PERIOD
• FIGURE 10 INCREASING USE OF LIPID NANOPARTICLES IN RNA-BASED THERAPIES TO PROPEL LNP RAW MATERIALS MARKET
• FIGURE 11 US AND IONIZABLE LIPIDS ACCOUNTED FOR LARGEST MARKET SHARES IN NORTH AMERICA IN 2025
• FIGURE 12 ASIA PACIFIC COUNTRIES TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
• FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 14 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO DOMINATE MARKET DURING FORECAST PERIOD
• FIGURE 15 LIPID NANOPARTICLES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
• FIGURE 16 LIPID NANOPARTICLES MARKET: PORTER'S FIVE FORCES ANALYSIS
• FIGURE 17 LNP RAW MATERIALS MARKET: VALUE CHAIN ANALYSIS
• FIGURE 18 LNP SERVICES MARKET: VALUE CHAIN ANALYSIS
• FIGURE 19 LIPID NANOPARTICLES MARKET ECOSYSTEM
• FIGURE 20 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN THE LIPID NANOPARTICLES MARKET
• FIGURE 21 TOP APPLICANTS & OWNERS (COMPANIES) FOR LIPID NANOPARTICLE PATENTS, 2015-DECEMBER 2025
• FIGURE 22 IMPACT OF AI/GEN AI ON LIPID NANOPARTICLES MARKET
• FIGURE 23 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY OFFERING
• FIGURE 24 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE RAW MATERIALS, BY END USER
• FIGURE 25 KEY BUYING CRITERIA FOR LIPID NANOPARTICLE SERVICES, BY END USER
• FIGURE 26 NORTH AMERICA: LNP RAW MATERIALS MARKET SNAPSHOT
• FIGURE 27 ASIA PACIFIC: LNP RAW MATERIALS MARKET SNAPSHOT
• FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN LNP RAW MATERIALS MARKET, 2019-2025 (USD MILLION)
• FIGURE 29 MARKET SHARE ANALYSIS OF KEY PLAYERS IN LNP RAW MATERIALS MARKET (2025)
• FIGURE 30 LIPID NANOPARTICLES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
• FIGURE 31 LIPID NANOPARTICLES MARKET: COMPANY FOOTPRINT
• FIGURE 32 LIPID NANOPARTICLES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
• FIGURE 33 EV/EBITDA OF KEY VENDORS
• FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
• FIGURE 35 LIPID NANOPARTICLES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
• FIGURE 36 AVANTI POLAR LIPIDS (CRODA INTERNATIONAL PLC): COMPANY SNAPSHOT (2025)
• FIGURE 37 MERCK KGAA: COMPANY SNAPSHOT (2025)
• FIGURE 38 EVONIK INDUSTRIES AG: COMPANY SNAPSHOT (2025)
• FIGURE 39 NIPPON FINE CHEMICAL CO., LTD.: COMPANY SNAPSHOT (2025)
• FIGURE 40 NOF CORPORATION: COMPANY SNAPSHOT (2025)
• FIGURE 41 FUJIFILM PHARMACEUTICALS U.S.A., INC.: COMPANY SNAPSHOT (2025)
• FIGURE 42 RECIPHARM AB: COMPANY SNAPSHOT (2025)
• FIGURE 43 EMERGENT: COMPANY SNAPSHOT (2025)
• FIGURE 44 EUROAPI: COMPANY SNAPSHOT (2025)
• FIGURE 45 IOI OLEO GMBH: COMPANY SNAPSHOT (2025)
• FIGURE 46 RESEARCH DESIGN
• FIGURE 47 LNP RAW MATERIALS & SERVICES MARKET: BREAKDOWN OF PRIMARIES
• FIGURE 48 LNP RAW MATERIALS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
• FIGURE 49 LNP SERVICES MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2025
• FIGURE 50 MARKET SIZE ESTIMATION (RAW MATERIALS): APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
• FIGURE 51 MARKET SIZE ESTIMATION (SERVICES): APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2025
• FIGURE 52 ILLUSTRATIVE EXAMPLE OF NOF CORPORATION: REVENUE SHARE ANALYSIS (2025)
• FIGURE 53 MARKET SIZE VALIDATION FROM PRIMARY SOURCES
• FIGURE 54 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH
• FIGURE 55 LNP RAW MATERIALS MARKET (SUPPLY SIDE): CAGR PROJECTIONS
• FIGURE 56 LNP SERVICES MARKET (SUPPLY SIDE): CAGR PROJECTIONS
• FIGURE 57 DATA TRIANGULATION METHODOLOGY